Pharma BD Deal Intelligence

Oruka Therapeutics, Inc. / Halozyme Therapeutics, Inc.

2026 · Licensing/Option · Complete

Halozyme Therapeutics and Oruka Therapeutics entered a global exclusive collaboration and license agreement giving Oruka rights to Halozyme's Hypercon high-concentration formulation technology for use with ORKA-001, Oruka's antibody in development for plaque psoriasis and related inflammatory diseases, plus an option for up to one additional target. Oruka pays an undisclosed upfront payment and Halozyme is eligible for milestone payments and royalties on net sales. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals